Telo Genomics Corp. develops diagnostic and prognostic tests for human disease using 3D analysis of chromosomal telomeres. News about TDSGF centers on the company’s telomere analytics platform, including TeloView® and blood-based minimal residual disease testing for multiple myeloma.
Recurring updates include retrospective clinical studies and academic collaborations, presentations at hematology and myeloma meetings, laboratory-capacity developments, and corporate governance changes. Company announcements also describe work with circulating tumor cells, individual-cell risk profiling, and the use of liquid-biopsy workflows to assess relapse risk in oncology.
Telo Genomics (TDSGF) is expanding multi-center studies comparing its blood-based TELO-MRD test with Adaptive Biotechnologies' clonoSEQ in multiple myeloma. MRD means measurable residual disease: cancer remaining after treatment. TELO-MRD combines circulating tumor-cell counting with three-dimensional analysis of chromosome ends.
The company schedules comparative testing of the University of Nantes IFM 2018-04 cohort for calendar fourth quarter 2026. It is obtaining approximately 25-30 samples from the University of Athens with existing clonoSEQ results. Montreal's Jewish General Hospital has identified 10 additional monitoring time points, subject to corresponding sequencing results being available. Cleveland Clinic is recruiting patients with existing clonoSEQ results.
The company targets commercial application by the end of calendar 2027. These research comparisons are not a basis for treatment decisions; results require larger, independent confirmation.
Telo Genomics (TDSGF) reported research comparing blood-based manual TELO cell counts with matched bone-marrow Adaptive clonoSEQ tests in multiple myeloma.
Across 17 matched comparisons from Cleveland Clinic and Jewish General Hospital, including baseline and follow-up samples, TELO found circulating plasma cells in every evaluable specimen. In 10 longitudinal assessments, TELO was positive in all 5 Adaptive-positive or Positive-Below-Limit-of-Detection samples, all 4 Adaptive-negative samples and the 1 sample Adaptive could not evaluate.
In an earlier, separate comparison, TELO-MRD detected circulating myeloma cells in 39 of 42 matched samples, versus MRD detection by bone-marrow EuroFlow in 23 of 42. The Adaptive dataset is small and used manual counts; the blood and marrow results are not interchangeable or a basis for treatment decisions. TELO-MRD is not commercially available. Telo intends to validate automated workflows and aims for a commercial application by the end of 2027.
Telo Genomics (TDSGF) reported clinical research results showing its TELO-MRD blood assay detected residual myeloma cells in 92.9% of matched samples.
In a University of Athens comparison of 42 evaluable, date-matched samples, TELO-MRD was positive in 39/42 (92.9%; 95% CI 80.5%-98.5%) versus 23/42 (54.8%; 95% CI 38.7%-70.2%) for bone-marrow EuroFlow next-generation flow cytometry, with a statistically significant paired difference (McNemar P=0.000145). TELO-MRD remained positive in 17/19 NGF-negative samples and 22/23 NGF-positive samples.
The assay showed an analytical limit of detection of 1 myeloma cell per 10⁷ white blood cells and current relapse-risk modeling using 3D telomere parameters has area-under-the-curve performance around 0.8. Telo Genomics is introducing a TELO-MRD scoring model to estimate relapse risk and intends to pursue commercial application by the end of 2027 in an MRD testing market it estimates at US$300–400 million for multiple myeloma.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) granted stock options to purchase up to an aggregate of 3,300,000 common shares under its stock option plan, subject to TSX Venture Exchange approval. The grants allocate 2,500,000 options to directors and officers, 600,000 to employees and 200,000 to consultants. The options are exercisable at $0.055 per share, vest immediately and expire five years from the grant date.
According to Telo Genomics, the awards are intended to reward past and ongoing efforts and incentivize future contributions. Options granted to directors, officers and consultants, and the underlying shares, are subject to a four‑month hold period under TSX Venture Exchange policies.
Telo Genomics (OTCQB:TDSGF) reported positive interim results from an ongoing retrospective clinical study in multiple myeloma conducted with the National and Kapodistrian University of Athens. The trial evaluates baseline blood samples from patients treated with standard-of-care regimens and known two-year outcomes, comparing those who relapsed with those who remained in remission.
Interim analysis of 50 patients identified “Average Distance to Nuclear Center,” a telomere-associated nuclear architecture parameter linked to genomic instability, as the strongest predictor of relapse status. Receiver Operating Characteristic analysis showed an Area Under the Curve of 0.849, which the company describes as highly predictive. According to Telo Genomics, its blood-based 3D telomere assay may combine minimal residual disease detection, relapse-risk stratification, and longitudinal monitoring in a single test, and could reduce reliance on bone marrow biopsies. The company is also running additional MRD studies with Cleveland Clinic and Montreal Jewish General Hospital and plans broader validation through the end of 2026.
Telo Genomics (OTCQB:TDSGF) filed a U.S. provisional patent to extend its TeloView biomarker algorithm to liquid biopsy MRD applications for multiple myeloma. The patent covers relapse-risk prediction and a workflow for isolating circulating cancer cells, supporting future partnerships and IP protection reportedly through 2043.
Telo Genomics (OTCQB:TDSGF) announced the termination of its investor relations consulting agreement with Sheridan Adams, effective June 12, 2026. The engagement, originally disclosed March 31, 2026, was understood by both parties to be a short-term, transitory role. Telo Genomics extended best wishes to Sheridan.
Telo Genomics (OTCQB: TDSGF) launched a retrospective clinical study with the National and Kapodistrian University of Athens to validate a blood-based 3D telomere assay for MRD in multiple myeloma. The study will compare baseline blood samples to two-year outcomes and aims to match or exceed Euroflow sensitivity.
The company expects results in summer 2026 and renewed CAP laboratory accreditation supports its commercialization pathway and expanded testing capabilities.
Telo Genomics (OTCQB: TDSGF) appointed John Farlinger as chief executive officer and chairman effective March 31, 2026, succeeding founder Dr. Sabine Mai, who remains a director. The company granted Mr. Farlinger 3,700,000 options at $0.055 (50% vested) and engaged Sheridan Adams for investor relations, receiving 250,000 options at $0.05. Telo Genomics expects clinical study results by summer 2026, is beginning work toward a U.S. FDA application, and targets Medicare reimbursement in 2027.
Telo Genomics (OTCQB: TDSGF) appointed John Price as Chief Financial Officer, effective January 30, 2026. Mr. Price brings over three decades of accounting, financial planning, M&A and capital markets experience and succeeds Christopher Ross, who served as CFO since April 2021.
Mr. Price worked at public companies including Assure Holdings, National Beverage, Alliance MMA and MusclePharm, held finance roles at Silicon Valley technology firms, and began his career at Ernst & Young. He holds a B.S. in Accounting from Pennsylvania State University and has no family ties to company directors or officers.